Global Zika Virus Testing research
Global Zika Virus Testing research

Zika Virus Testing Comprehensive Study by Technology (Molecular Test, Serologic Test, Plaque Reduction Neutralization Test (PRNT)), End User (Hospital/Clinic, Diagnostics Laboratory, Academic and Research Institutes, Others) Players and Region - Global Market Outlook to 2024

Zika Virus Testing Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025 | CAGR: 5.5%  

Feb 2019 Edition 241 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Industry Background:
Zika is a viral infection generally spread by mosquitos. Zika virus can also spread through sex with an infected person or from a pregnant woman to her baby. A Zika virus test looks for signs of the infection in urine or blood. Mosquitos that carry the Zika virus are most common in areas of the world with tropical climates. These include islands in the Caribbean and the Pacific, Central America, some parts of Africa, South America, and Mexico. Mosquitos carrying the Zika virus have also been found in parts of the United States, including South Florida. A Zika virus test is used to find out whether the person has been infected with Zika infection. The test is usually applied on pregnant women who have recently traveled to an area where there is a risk of Zika infection.According to AMA, the market for Zika Virus Testing is expected to register a CAGR of 5.5% during the forecast period to 2024. This growth is primarily driven by Increasing Prevalence of Zika Virus Infection, Government Initiatives to Develop Innovative Tests, Increasing R&D by Biopharmaceutical Companies and Technological Advancements in Medical Diagnostics.

The Diseases & Therapeutic Areas sector in the North America region has been increasing at a strong rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Abbott (United States), Altona Diagnostics GmbH (Germany), Chembio Diagnostic Systems Inc. (United States), ELITechGroup (France), F. Hoffmann-La Roche Ltd (Switzerland), Fast Track Diagnostics Ltd (Luxembourg), Genekam (Germany), Luminex Corporation (United States), Primerdesign Ltd (United Kingdom) and Quest Diagnostics (United States) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

On 6 Oct 2017, FDA has approved Roche cobas Zika as first commercially-available donor screening test for Zika virus. and On 2 Feb. 2017 Abbott has announced that the U.S. Food and Drug Administration (FDA) has authorized its molecular test, the Abbott RealTime ZIKA test, to detect Zika virus in whole blood for emergency use. It is the preliminary molecular test completed by a commercial manufacturer official to detect Zika in whole blood samples, which is significant since recent research suggests Zika virus can be detected in whole blood for a longer period of time and at higher levels versus testing with serum and urine sample types.

Market Drivers
  • Increasing Prevalence of Zika Virus Infection
  • Government Initiatives to Develop Innovative Tests
  • Increasing R&D by Biopharmaceutical Companies
  • Technological Advancements in Medical Diagnostics

Market Trend

Restraints
  • High Costs of Testing Kits
  • Sluggish Adoption of New Technologies in the Emerging Markets

Opportunities
Rising Adoption of New Technologies in the Medical Device Sector

AdvanceMarketAnalytics follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization of the Report:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Technology
  • Molecular Test
  • Serologic Test
  • Plaque Reduction Neutralization Test (PRNT)

By End User
  • Hospital/Clinic
  • Diagnostics Laboratory
  • Academic and Research Institutes
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Zika Virus Infection
      • 3.2.2. Government Initiatives to Develop Innovative Tests
      • 3.2.3. Increasing R&D by Biopharmaceutical Companies
      • 3.2.4. Technological Advancements in Medical Diagnostics
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Zika Virus Testing, by Technology, End User and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Zika Virus Testing (Value)
      • 5.2.1. Global Zika Virus Testing by: Technology (Value)
        • 5.2.1.1. Molecular Test
        • 5.2.1.2. Serologic Test
        • 5.2.1.3. Plaque Reduction Neutralization Test (PRNT)
      • 5.2.2. Global Zika Virus Testing by: End User (Value)
        • 5.2.2.1. Hospital/Clinic
        • 5.2.2.2. Diagnostics Laboratory
        • 5.2.2.3. Academic and Research Institutes
        • 5.2.2.4. Others
      • 5.2.3. Global Zika Virus Testing Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Zika Virus Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Altona Diagnostics GmbH (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Chembio Diagnostic Systems Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. ELITechGroup (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Fast Track Diagnostics Ltd (Luxembourg)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Genekam (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Luminex Corporation (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Primerdesign Ltd (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Quest Diagnostics (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Zika Virus Testing Sale, by Technology, End User and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Zika Virus Testing (Value)
      • 7.2.1. Global Zika Virus Testing by: Technology (Value)
        • 7.2.1.1. Molecular Test
        • 7.2.1.2. Serologic Test
        • 7.2.1.3. Plaque Reduction Neutralization Test (PRNT)
      • 7.2.2. Global Zika Virus Testing by: End User (Value)
        • 7.2.2.1. Hospital/Clinic
        • 7.2.2.2. Diagnostics Laboratory
        • 7.2.2.3. Academic and Research Institutes
        • 7.2.2.4. Others
      • 7.2.3. Global Zika Virus Testing Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Zika Virus Testing: by Technology(USD Million)
  • Table 2. Zika Virus Testing Molecular Test , by Region USD Million (2013-2018)
  • Table 3. Zika Virus Testing Serologic Test , by Region USD Million (2013-2018)
  • Table 4. Zika Virus Testing Plaque Reduction Neutralization Test (PRNT) , by Region USD Million (2013-2018)
  • Table 5. Zika Virus Testing: by End User(USD Million)
  • Table 6. Zika Virus Testing Hospital/Clinic , by Region USD Million (2013-2018)
  • Table 7. Zika Virus Testing Diagnostics Laboratory , by Region USD Million (2013-2018)
  • Table 8. Zika Virus Testing Academic and Research Institutes , by Region USD Million (2013-2018)
  • Table 9. Zika Virus Testing Others , by Region USD Million (2013-2018)
  • Table 10. South America Zika Virus Testing, by Country USD Million (2013-2018)
  • Table 11. South America Zika Virus Testing, by Technology USD Million (2013-2018)
  • Table 12. South America Zika Virus Testing, by End User USD Million (2013-2018)
  • Table 13. Brazil Zika Virus Testing, by Technology USD Million (2013-2018)
  • Table 14. Brazil Zika Virus Testing, by End User USD Million (2013-2018)
  • Table 15. Argentina Zika Virus Testing, by Technology USD Million (2013-2018)
  • Table 16. Argentina Zika Virus Testing, by End User USD Million (2013-2018)
  • Table 17. Rest of South America Zika Virus Testing, by Technology USD Million (2013-2018)
  • Table 18. Rest of South America Zika Virus Testing, by End User USD Million (2013-2018)
  • Table 19. Asia Pacific Zika Virus Testing, by Country USD Million (2013-2018)
  • Table 20. Asia Pacific Zika Virus Testing, by Technology USD Million (2013-2018)
  • Table 21. Asia Pacific Zika Virus Testing, by End User USD Million (2013-2018)
  • Table 22. China Zika Virus Testing, by Technology USD Million (2013-2018)
  • Table 23. China Zika Virus Testing, by End User USD Million (2013-2018)
  • Table 24. Japan Zika Virus Testing, by Technology USD Million (2013-2018)
  • Table 25. Japan Zika Virus Testing, by End User USD Million (2013-2018)
  • Table 26. India Zika Virus Testing, by Technology USD Million (2013-2018)
  • Table 27. India Zika Virus Testing, by End User USD Million (2013-2018)
  • Table 28. South Korea Zika Virus Testing, by Technology USD Million (2013-2018)
  • Table 29. South Korea Zika Virus Testing, by End User USD Million (2013-2018)
  • Table 30. Taiwan Zika Virus Testing, by Technology USD Million (2013-2018)
  • Table 31. Taiwan Zika Virus Testing, by End User USD Million (2013-2018)
  • Table 32. Australia Zika Virus Testing, by Technology USD Million (2013-2018)
  • Table 33. Australia Zika Virus Testing, by End User USD Million (2013-2018)
  • Table 34. Rest of Asia-Pacific Zika Virus Testing, by Technology USD Million (2013-2018)
  • Table 35. Rest of Asia-Pacific Zika Virus Testing, by End User USD Million (2013-2018)
  • Table 36. Europe Zika Virus Testing, by Country USD Million (2013-2018)
  • Table 37. Europe Zika Virus Testing, by Technology USD Million (2013-2018)
  • Table 38. Europe Zika Virus Testing, by End User USD Million (2013-2018)
  • Table 39. Germany Zika Virus Testing, by Technology USD Million (2013-2018)
  • Table 40. Germany Zika Virus Testing, by End User USD Million (2013-2018)
  • Table 41. France Zika Virus Testing, by Technology USD Million (2013-2018)
  • Table 42. France Zika Virus Testing, by End User USD Million (2013-2018)
  • Table 43. Italy Zika Virus Testing, by Technology USD Million (2013-2018)
  • Table 44. Italy Zika Virus Testing, by End User USD Million (2013-2018)
  • Table 45. United Kingdom Zika Virus Testing, by Technology USD Million (2013-2018)
  • Table 46. United Kingdom Zika Virus Testing, by End User USD Million (2013-2018)
  • Table 47. Netherlands Zika Virus Testing, by Technology USD Million (2013-2018)
  • Table 48. Netherlands Zika Virus Testing, by End User USD Million (2013-2018)
  • Table 49. Rest of Europe Zika Virus Testing, by Technology USD Million (2013-2018)
  • Table 50. Rest of Europe Zika Virus Testing, by End User USD Million (2013-2018)
  • Table 51. MEA Zika Virus Testing, by Country USD Million (2013-2018)
  • Table 52. MEA Zika Virus Testing, by Technology USD Million (2013-2018)
  • Table 53. MEA Zika Virus Testing, by End User USD Million (2013-2018)
  • Table 54. Middle East Zika Virus Testing, by Technology USD Million (2013-2018)
  • Table 55. Middle East Zika Virus Testing, by End User USD Million (2013-2018)
  • Table 56. Africa Zika Virus Testing, by Technology USD Million (2013-2018)
  • Table 57. Africa Zika Virus Testing, by End User USD Million (2013-2018)
  • Table 58. North America Zika Virus Testing, by Country USD Million (2013-2018)
  • Table 59. North America Zika Virus Testing, by Technology USD Million (2013-2018)
  • Table 60. North America Zika Virus Testing, by End User USD Million (2013-2018)
  • Table 61. United States Zika Virus Testing, by Technology USD Million (2013-2018)
  • Table 62. United States Zika Virus Testing, by End User USD Million (2013-2018)
  • Table 63. Canada Zika Virus Testing, by Technology USD Million (2013-2018)
  • Table 64. Canada Zika Virus Testing, by End User USD Million (2013-2018)
  • Table 65. Mexico Zika Virus Testing, by Technology USD Million (2013-2018)
  • Table 66. Mexico Zika Virus Testing, by End User USD Million (2013-2018)
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Zika Virus Testing: by Technology(USD Million)
  • Table 78. Zika Virus Testing Molecular Test , by Region USD Million (2019-2024)
  • Table 79. Zika Virus Testing Serologic Test , by Region USD Million (2019-2024)
  • Table 80. Zika Virus Testing Plaque Reduction Neutralization Test (PRNT) , by Region USD Million (2019-2024)
  • Table 81. Zika Virus Testing: by End User(USD Million)
  • Table 82. Zika Virus Testing Hospital/Clinic , by Region USD Million (2019-2024)
  • Table 83. Zika Virus Testing Diagnostics Laboratory , by Region USD Million (2019-2024)
  • Table 84. Zika Virus Testing Academic and Research Institutes , by Region USD Million (2019-2024)
  • Table 85. Zika Virus Testing Others , by Region USD Million (2019-2024)
  • Table 86. South America Zika Virus Testing, by Country USD Million (2019-2024)
  • Table 87. South America Zika Virus Testing, by Technology USD Million (2019-2024)
  • Table 88. South America Zika Virus Testing, by End User USD Million (2019-2024)
  • Table 89. Brazil Zika Virus Testing, by Technology USD Million (2019-2024)
  • Table 90. Brazil Zika Virus Testing, by End User USD Million (2019-2024)
  • Table 91. Argentina Zika Virus Testing, by Technology USD Million (2019-2024)
  • Table 92. Argentina Zika Virus Testing, by End User USD Million (2019-2024)
  • Table 93. Rest of South America Zika Virus Testing, by Technology USD Million (2019-2024)
  • Table 94. Rest of South America Zika Virus Testing, by End User USD Million (2019-2024)
  • Table 95. Asia Pacific Zika Virus Testing, by Country USD Million (2019-2024)
  • Table 96. Asia Pacific Zika Virus Testing, by Technology USD Million (2019-2024)
  • Table 97. Asia Pacific Zika Virus Testing, by End User USD Million (2019-2024)
  • Table 98. China Zika Virus Testing, by Technology USD Million (2019-2024)
  • Table 99. China Zika Virus Testing, by End User USD Million (2019-2024)
  • Table 100. Japan Zika Virus Testing, by Technology USD Million (2019-2024)
  • Table 101. Japan Zika Virus Testing, by End User USD Million (2019-2024)
  • Table 102. India Zika Virus Testing, by Technology USD Million (2019-2024)
  • Table 103. India Zika Virus Testing, by End User USD Million (2019-2024)
  • Table 104. South Korea Zika Virus Testing, by Technology USD Million (2019-2024)
  • Table 105. South Korea Zika Virus Testing, by End User USD Million (2019-2024)
  • Table 106. Taiwan Zika Virus Testing, by Technology USD Million (2019-2024)
  • Table 107. Taiwan Zika Virus Testing, by End User USD Million (2019-2024)
  • Table 108. Australia Zika Virus Testing, by Technology USD Million (2019-2024)
  • Table 109. Australia Zika Virus Testing, by End User USD Million (2019-2024)
  • Table 110. Rest of Asia-Pacific Zika Virus Testing, by Technology USD Million (2019-2024)
  • Table 111. Rest of Asia-Pacific Zika Virus Testing, by End User USD Million (2019-2024)
  • Table 112. Europe Zika Virus Testing, by Country USD Million (2019-2024)
  • Table 113. Europe Zika Virus Testing, by Technology USD Million (2019-2024)
  • Table 114. Europe Zika Virus Testing, by End User USD Million (2019-2024)
  • Table 115. Germany Zika Virus Testing, by Technology USD Million (2019-2024)
  • Table 116. Germany Zika Virus Testing, by End User USD Million (2019-2024)
  • Table 117. France Zika Virus Testing, by Technology USD Million (2019-2024)
  • Table 118. France Zika Virus Testing, by End User USD Million (2019-2024)
  • Table 119. Italy Zika Virus Testing, by Technology USD Million (2019-2024)
  • Table 120. Italy Zika Virus Testing, by End User USD Million (2019-2024)
  • Table 121. United Kingdom Zika Virus Testing, by Technology USD Million (2019-2024)
  • Table 122. United Kingdom Zika Virus Testing, by End User USD Million (2019-2024)
  • Table 123. Netherlands Zika Virus Testing, by Technology USD Million (2019-2024)
  • Table 124. Netherlands Zika Virus Testing, by End User USD Million (2019-2024)
  • Table 125. Rest of Europe Zika Virus Testing, by Technology USD Million (2019-2024)
  • Table 126. Rest of Europe Zika Virus Testing, by End User USD Million (2019-2024)
  • Table 127. MEA Zika Virus Testing, by Country USD Million (2019-2024)
  • Table 128. MEA Zika Virus Testing, by Technology USD Million (2019-2024)
  • Table 129. MEA Zika Virus Testing, by End User USD Million (2019-2024)
  • Table 130. Middle East Zika Virus Testing, by Technology USD Million (2019-2024)
  • Table 131. Middle East Zika Virus Testing, by End User USD Million (2019-2024)
  • Table 132. Africa Zika Virus Testing, by Technology USD Million (2019-2024)
  • Table 133. Africa Zika Virus Testing, by End User USD Million (2019-2024)
  • Table 134. North America Zika Virus Testing, by Country USD Million (2019-2024)
  • Table 135. North America Zika Virus Testing, by Technology USD Million (2019-2024)
  • Table 136. North America Zika Virus Testing, by End User USD Million (2019-2024)
  • Table 137. United States Zika Virus Testing, by Technology USD Million (2019-2024)
  • Table 138. United States Zika Virus Testing, by End User USD Million (2019-2024)
  • Table 139. Canada Zika Virus Testing, by Technology USD Million (2019-2024)
  • Table 140. Canada Zika Virus Testing, by End User USD Million (2019-2024)
  • Table 141. Mexico Zika Virus Testing, by Technology USD Million (2019-2024)
  • Table 142. Mexico Zika Virus Testing, by End User USD Million (2019-2024)
  • Table 143. Research Programs/Design for This Report
  • Table 144. Key Data Information from Secondary Sources
  • Table 145. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Zika Virus Testing: by Technology USD Million (2013-2018)
  • Figure 5. Global Zika Virus Testing: by End User USD Million (2013-2018)
  • Figure 6. South America Zika Virus Testing Share (%), by Country
  • Figure 7. Asia Pacific Zika Virus Testing Share (%), by Country
  • Figure 8. Europe Zika Virus Testing Share (%), by Country
  • Figure 9. MEA Zika Virus Testing Share (%), by Country
  • Figure 10. North America Zika Virus Testing Share (%), by Country
  • Figure 11. Global Zika Virus Testing share by Players 2018 (%)
  • Figure 12. Global Zika Virus Testing share by Players (Top 3) 2018(%)
  • Figure 13. Global Zika Virus Testing share by Players (Top 5) 2018(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 16. Abbott (United States) Revenue: by Geography 2018
  • Figure 17. Altona Diagnostics GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 18. Altona Diagnostics GmbH (Germany) Revenue: by Geography 2018
  • Figure 19. Chembio Diagnostic Systems Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Chembio Diagnostic Systems Inc. (United States) Revenue: by Geography 2018
  • Figure 21. ELITechGroup (France) Revenue, Net Income and Gross profit
  • Figure 22. ELITechGroup (France) Revenue: by Geography 2018
  • Figure 23. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2018
  • Figure 25. Fast Track Diagnostics Ltd (Luxembourg) Revenue, Net Income and Gross profit
  • Figure 26. Fast Track Diagnostics Ltd (Luxembourg) Revenue: by Geography 2018
  • Figure 27. Genekam (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Genekam (Germany) Revenue: by Geography 2018
  • Figure 29. Luminex Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 30. Luminex Corporation (United States) Revenue: by Geography 2018
  • Figure 31. Primerdesign Ltd (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. Primerdesign Ltd (United Kingdom) Revenue: by Geography 2018
  • Figure 33. Quest Diagnostics (United States) Revenue, Net Income and Gross profit
  • Figure 34. Quest Diagnostics (United States) Revenue: by Geography 2018
  • Figure 35. Global Zika Virus Testing: by Technology USD Million (2019-2024)
  • Figure 36. Global Zika Virus Testing: by End User USD Million (2019-2024)
  • Figure 37. South America Zika Virus Testing Share (%), by Country
  • Figure 38. Asia Pacific Zika Virus Testing Share (%), by Country
  • Figure 39. Europe Zika Virus Testing Share (%), by Country
  • Figure 40. MEA Zika Virus Testing Share (%), by Country
  • Figure 41. North America Zika Virus Testing Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Abbott (United States)
  • Altona Diagnostics GmbH (Germany)
  • Chembio Diagnostic Systems Inc. (United States)
  • ELITechGroup (France)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Fast Track Diagnostics Ltd (Luxembourg)
  • Genekam (Germany)
  • Luminex Corporation (United States)
  • Primerdesign Ltd (United Kingdom)
  • Quest Diagnostics (United States)
Additional players considered in the study are as follows:
Aalto Bio Reagents (Ireland) , Inovio (United States) , Swiss (Switzerland) , ChembioDiagnostics (United States) , Roche (Switzerland) , Cerus Corporation (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation